Hypertension Drug's Labeling Problems Prompt GSK Recall

By Sindhu Sundar

Law360, New York (February 24, 2012, 9:25 PM ET) -- GlaxoSmithKline PLC will recall some 394,000 bottles of a blood-pressure medication in the U.S. after drug labeling problems were revealed at a Novartis AG plant in Nebraska that supplies the medication, the drugmaker said Friday.

GSK referred to “inconsistent packaging line-clearance practices” at Novartis’ Lincoln, Neb., facility saying that even though it had not received any complaints about the wrong drugs in its batches of blood pressure drug DynaCirc CR, it would implement the recall as a precautionary measure against such possible tablet mix-ups.